Langdahl B L, Løkke E, Carstens M, Stenkjaer L L, Eriksen E F
Department of Endocrinology and Metabolism, Aarhus University Hospital, Aarhus Amtssygehus, Denmark.
J Bone Miner Res. 2000 Mar;15(3):402-14. doi: 10.1359/jbmr.2000.15.3.402.
Interleukin-1beta (IL-1beta) is a potent stimulator of bone resorption, and has been implicated in the pathogenesis of high bone turnover and osteoporosis. IL-1 receptor antagonist (IL-1ra) is a competitive inhibitor of IL-1beta effects and the biological effects of IL-1beta are therefore proportional to the ratio IL-1beta/IL-1ra. The coding regions of IL-1beta were examined for sequence variations by SSCP and sequencing after polymerase chain reaction (PCR) of genomic DNA. Three previously described polymorphisms (C(-511)-T, G(3877)-A and C(3954)-T) in the IL-1beta gene were determined by restriction fragment length polymorphism (RFLP) using Ava I, Aci I, and Taq I after PCR. The 86-base pair repeat polymorphism in IL-1ra was examined by PCR and electrophoresis and the T11100-C polymorphism in the IL-1ra gene was examined by RFLP using MspA1I after PCR. All polymorphisms were related to bone mass, biochemical markers of bone turnover, and presence of fracture in a study including 389 osteoporotic patients with vertebral fractures and normal controls. Two normal women were heterozygous for a shift from cytosine to thymine (C3263-T) in exon 4 of the IL-1beta gene. This substitution did not affect the amino acid sequence. We did not find other sequence variations in the IL-1beta gene apart from the already known polymorphisms. The distribution of C(-511)-T, G(3877)-A, and C(3954)-T genotypes was similar in the osteoporotic and the normal controls. No significant differences could be shown in bone mass or bone turnover. In the IL-1ra gene almost complete linkage was confirmed between the already known polymorphisms: G(1731)-A, G(1821)-A, A(1868)-G, G(1887)-C, T(8006)-C, C(8061)-T, 86 base pair variable number tandem repeat (VNTR), A(9589)-T, and a new polymorphism: T(1934)-C. The A1A1/A3 genotypes of the IL-1ra VNTR polymorphism were significantly more frequent in osteoporotic patients (56.2%) compared with age-matched normal controls (43.3%) (chi2 = 4.09; p = 0.043). The relative risk of osteoporotic fractures was increased to 1.68 (95% CI, 1.01-2.77) in individuals with A1A1/A3 genotypes. Bone mineral density (BMD) of the lumbar spine was reduced in individuals with A1A1/A3 genotypes (p = 0.014, analysis of variance [ANOVA]). The difference in bone mass between A1A1/A3 and A2A1/A2 tended to increase with increasing age. T1100-C genotypes were distributed similarly in osteoporotic patients and normal controls and the polymorphism was without effect on bone mass and biochemical markers of bone turnover. In conclusion, an 86-base pair repeat polymorphism in the IL-lra gene is associated with increased risk of osteoporotic fractures. Other polymorphisms in the IL-1ra and the IL-1beta genes are not associated with osteoporotic fractures or alterations in bone mass or bone turnover.
白细胞介素-1β(IL-1β)是骨吸收的强效刺激因子,与高骨转换和骨质疏松症的发病机制有关。白细胞介素-1受体拮抗剂(IL-1ra)是IL-1β效应的竞争性抑制剂,因此IL-1β的生物学效应与IL-1β/IL-1ra的比值成正比。通过对基因组DNA进行聚合酶链反应(PCR)后,采用单链构象多态性(SSCP)和测序技术检测IL-1β的编码区序列变异。PCR后,使用Ava I、Aci I和Taq I通过限制性片段长度多态性(RFLP)确定IL-1β基因中三个先前描述的多态性(C(-511)-T、G(3877)-A和C(3954)-T)。通过PCR和电泳检测IL-1ra中的86碱基对重复多态性,PCR后使用MspA1I通过RFLP检测IL-1ra基因中的T11100-C多态性。在一项纳入389例患有椎体骨折的骨质疏松症患者和正常对照的研究中,所有多态性均与骨量、骨转换生化标志物及骨折的发生相关。两名正常女性在IL-1β基因外显子4中存在从胞嘧啶到胸腺嘧啶(C3263-T)的杂合性转换。这种替代不影响氨基酸序列。除了已知的多态性外,我们在IL-1β基因中未发现其他序列变异。骨质疏松症患者和正常对照中C(-511)-T、G(3877)-A和C(3954)-T基因型的分布相似。在骨量或骨转换方面未显示出显著差异。在IL-1ra基因中,已证实已知多态性之间几乎完全连锁:G(1731)-A、G(1821)-A、A(1868)-G、G(1887)-C、T(8006)-C、C(8061)-T、86碱基对可变数目串联重复序列(VNTR)、A(9589)-T以及一个新的多态性:T(1934)-C。与年龄匹配的正常对照(43.3%)相比,IL-1ra VNTR多态性的A1A1/A3基因型在骨质疏松症患者中显著更常见(56.2%)(χ2 = 4.09;P = 0.043)。A1A1/A3基因型个体发生骨质疏松性骨折的相对风险增加至1.68(95%可信区间,1.01 - 2.77)。A1A1/A3基因型个体的腰椎骨密度(BMD)降低(P = 0.014,方差分析[ANOVA])。A1A1/A3与A2A1/A2之间的骨量差异倾向于随年龄增加而增大。T1100-C基因型在骨质疏松症患者和正常对照中的分布相似,该多态性对骨量和骨转换生化标志物无影响。总之,IL-1ra基因中的86碱基对重复多态性与骨质疏松性骨折风险增加相关。IL-1ra和IL-1β基因中的其他多态性与骨质疏松性骨折或骨量及骨转换改变无关。